A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ...

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal ...

The data, first presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, showed that the phase 3 ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

"Zymeworks reports Phase I data for ZW191 ADC" was originally created and published by Clinical Trials Arena, a GlobalData ...

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) ...

Ibuprofen is a household name—the go-to remedy for everything from headaches to period pain. But recent research suggests ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...

A common painkiller, ibuprofen, is showing surprising potential beyond easing aches. Research suggests it might help combat ...

Step Pharma is financed to move its pipeline-in-a-product strategy forward on a broad front, after raising a €38 million (US$44.2 million) series C. That will see three ongoing trials testing the ...

Investing.com -- PMV Pharmaceuticals Inc (NASDAQ:PMVP) stock rose 2.2% on Friday after the company reported encouraging clinical trial results for its cancer drug rezatapopt, showing responses across ...